We will rely on you to help lend your voice and support the biotechnology industry.
Bringing new treatments to patients, support public policies that promote innovation, improve patient access.
BIO Latin America Conference
September 4-5, 2018
BIO Investor Forum
October 17-18, 2018
BIO Industry Analysis Reports >>
Save. Advocate. Connect. Join Us.
A listing of all BIO members and subsidiaries.
October 17 - 18, 2018 | San Francisco, California
Dr Krol is currently Chief Development Officer of Axolo Pharma, a JV to develop and commercialize injetable MG53. Tom was previously Managing Director at the Kansas Bioscience Authority (KBA), a $580 million fund created by the state of Kansas, where he led human health investment activities.
Tom has more than 25 years of biopharma experience spanning multiple roles in R&D, technology assessment, marketing, L&BD for bigpharma and start-up pharma. Tom had multiple roles at Oakwood Labs, Verenta Pharmaceuticals, CyDex- Ligand, Pharmacia-Pfizer, Searle, Sanofi-Aventis and predecessor companies, including Marion Laboratories.
This speaker's sessions: